Search

Your search keyword '"OVERALL survival"' showing total 11 results
Start Over Descriptor "OVERALL survival" Publication Year Range Last 50 years Database Academic Search Index Publisher mjh life sciences
11 results on '"OVERALL survival"'

1. 18-Month Survival Results of Neoadjuvant Cemiplimab in Advanced Resectable CSCC May Lead to Reconsideration of Adjuvant Treatment.

Author

Joszt, Laura

Subjects
*DRUG efficacy, *IMMUNE checkpoint inhibitors, *CANCER relapse, *SKIN tumors, *COMBINED modality therapy, *SQUAMOUS cell carcinoma, *PREANESTHETIC medication, *OVERALL survival
Abstract

The article reports on the results of a phase 2 trial on the use of the neoadjuvant cemplimab in treating patients with resectable stage II to stage IV cutaneous squamous cell carcinoma (CSCC). According to Doctor Neil D. Gross of the University of Texas MD Anderson Cancer Center, the drug showed favorable survival results in patients with 51% of them showing pathologic complete response (pCR) rate per central review.

Published
2023

3. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.

Author

CLARKE, HANNAH and HOLLASCH, MEGAN

Subjects
*THERAPEUTIC use of monoclonal antibodies, *RISK assessment, *PLACEBOS, *DEATH, *CANCER relapse, *DRUG side effects, *PATIENT safety, *CLINICAL trials, *TERMINATION of treatment, *NEPHRECTOMY, *RENAL cell carcinoma, *DISEASE relapse, *PROGRESSION-free survival, *TUMOR classification, *OVERALL survival, *PATIENT aftercare, *EVALUATION, *DISEASE risk factors
Abstract

The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.

Published
2024

4. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.

Author

Cookson, Michael S.

Subjects
*NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

Published
2024

5. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.

Author

Joszt, Laura

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *DISEASE progression, *EVALUATION of human services programs, *COMBINATION drug therapy, *EPIDERMAL growth factor receptors, *LUNG tumors, *CHEMORADIOTHERAPY, *MEDICAL care research, *TUMOR classification, *TREATMENT effectiveness, *CANCER patients, *ANAPLASTIC lymphoma kinase, *SURVIVAL analysis (Biometry), *QUALITY of life, *PROGRESSION-free survival, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival, *CHEMICAL inhibitors
Abstract

The article reports on the results of the 3 EMPOWER-Lung 3 study that were presented at the 2023 European Society for Medical Oncology Congress, showing that cemiplimab plus chemotherapy showed better favorable survival benefits and patient-reported outcomes (PRO) in patients with advanced non-small cell lung cancer (NSCLC). Also cited are the median overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) study results.

Published
2023

6. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.

Author

Ryan, Chris

Subjects
*THERAPEUTIC use of antineoplastic agents, *DISEASE progression, *CARBOPLATIN, *CHEMORADIOTHERAPY, *PROGRESSION-free survival, *PACLITAXEL, *INDUCTION chemotherapy, *OVERALL survival, CERVIX uteri tumors
Abstract

The article reports on the results of the phase 3 INTERLACE trial showing that induction chemotherapy followed by chemoradiation lowered by 35% the risk of disease progression or death as compared to chemoradiation alone in patients with locally advanced cervical cancer. According to lead study author Mary McCormack, induction chemotherapy with paclitaxel and carboplatin should be considered as a standard treatment.

Published
2023

7. Prostate cancer treatment deintensification: When less is more.

Author

COOKSON, MICHAEL S.

Subjects
*PROSTATE tumors treatment, *DISEASE progression, *ANTIANDROGENS, *INDIVIDUALIZED medicine, *TREATMENT effectiveness, *RISK assessment, *ADVERSE health care events, *DISEASE management, *PROSTATE tumors, *OVERALL survival
Abstract

In the article, the author discusses updates in the treatment of patients with advanced and metastatic prostate cancer, particularly the clinical trials showing the efficacy of treatment deintensification in the proper clinical context. Other topics include the potential benefits of deintensification like reduction of treatment-related adverse events (TRAE) and the various deintensification methods like radiation therapy with omission of androgen deprivation therapy (ADT).

Published
2023

8. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG efficacy, *PATIENT aftercare, *COMBINATION drug therapy, *COLLEGE teacher attitudes, *TREATMENT effectiveness, *BENZAMIDE, *PROGRESSION-free survival, *OVERALL survival, *THERAPEUTICS
Abstract

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.

Published
2023

9. Diagnosis of Second Primary Malignancies Is Associated With Prolonged Survival Among Patients With MM.

Author

Gavidia, Matthew

Subjects
*CANCER patient psychology, *NOSOLOGY, *SECONDARY primary cancer, *MULTIPLE myeloma, *OVERALL survival
Abstract

The article discusses research that found a link between diagnosis of certain second primary malignancies (SPM) with increased overall survival among patients with multiple myeloma. Topics covered include nonmelanoma cutaneous cancer, breast cancer, and prostate cancer. The findings were presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Published
2023

10. Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.

Author

McNulty, Rose

Subjects
*MULTIPLE myeloma treatment, *DISEASE progression, *BONE marrow transplantation, *TREATMENT effectiveness, *PROGRESSION-free survival, *OVERALL survival
Abstract

The article discusses research that shows allogeneic stem cell transplant (allo-SCT) may not significantly benefit most patients with multiple myeloma. It considers the overall survival and progression-free survival after allo-SCT. The feasibility of alternatives such as CAR T-cell or bispecific T-cell engager therapies is suggested. The findings were presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Published
2023

11. Hypertension predicts worse outcomes for patients undergoing nephroureterectomy for UTUC.

Author

SAYLOR, BENJAMIN P.

Subjects
*URINARY organ surgery, *ONCOLOGIC surgery, *HYPERTENSION, *CAUSES of death, *NEPHRECTOMY, *URETHRA surgery, *SURGERY, *PATIENTS, *CANCER relapse, *TREATMENT effectiveness, *OVERALL survival, *DISEASE complications, MORTALITY risk factors
Abstract

The article provides information on data presented at the American Urological Association 2023 Annual Meeting in Chicago, Illinois which reported that hypertension is an independent predictor of worsened oncologic and survival outcomes in patients undergoing radical nephroureterectomy for the treatment of upper tract urothelial cancer (UTUC). Topics include rate of high tumor grade observed in patients with hypertension and overall survival of patients with hypertension.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results